Hartaj Singh
Stock Analyst at Oppenheimer
(1.76)
# 3,289
Out of 5,170 analysts
106
Total ratings
46.32%
Success rate
-7.1%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $16.65 | +122.22% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $737.45 | +22.04% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $141.11 | -11.42% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $458.05 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $59.05 | - | 6 | Dec 11, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $527.00 | +13.85% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $52.37 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $3.48 | +187.36% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.09 | +5,404.59% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.90 | +373.68% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.65 | +2,324.24% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $11.98 | +83.64% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.83 | - | 4 | Jul 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $5.20 | +12,400.00% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $15.72 | +90.84% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $16.65
Upside: +122.22%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $737.45
Upside: +22.04%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $141.11
Upside: -11.42%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $458.05
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $59.05
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $527.00
Upside: +13.85%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $52.37
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $3.48
Upside: +187.36%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.09
Upside: +5,404.59%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.90
Upside: +373.68%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.65
Upside: +2,324.24%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $11.98
Upside: +83.64%
Jul 5, 2023
Downgrades: Perform
Price Target: n/a
Current: $0.83
Upside: -
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $5.20
Upside: +12,400.00%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $15.72
Upside: +90.84%